Objective To evaluate outcomes of lower-energy selective laser trabeculoplasty (SLT) using a titrated energy–pigmentation (TAPE) construct.

Methods This retrospective study analyzed de-identified clinical data of 62 eyes undergoing lower-energy SLT as part of routine care. Laser energy was titrated relative to trabecular meshwork (TM) pigmentation grade and quantified as the product of the two (TAPE score). For example, grade 2 pigmentation × 40 mJ total energy yields a TAPE score of 80. The primary outcome was intraocular pressure (IOP) at 2 months, with adjustment for baseline maximum IOP (Tmax) using analysis of covariance (ANCOVA). Durability was assessed using Kaplan–Meier survival analysis and Cox proportional hazards modeling.

Results After adjustment for baseline Tmax, higher TAPE scores (≥70) were associated with lower 2-month IOP (p < 0.01) and greater likelihood of achieving ≥20% IOP reduction. Over longer follow-up, higher TAPE scores were associated with fewer treatment escalation events and improved survival free of additional therapy. Low-grade anterior chamber inflammation was common, transient, and self-limited. At 3 years, 85% of eyes in the high-TAPE group remained drop-free, accounting for retreatment where applicable. No clinically significant IOP spikes or sight-threatening adverse events were observed.

Conclusions Higher energy–pigmentation (TAPE) scores were associated with improved short-term IOP reduction and greater durability following lower-energy SLT. These findings are hypothesis-generating and suggest that TM pigmentation-adjusted energy delivery may enhance biologic engagement of the trabecular outflow pathway and support prospective evaluation of individualized SLT dosing strategies.

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study protocol was reviewed by an independent institutional review board (Solutions IRB) and determined to be exempt from formal review under 45 CFR 46.104(d)(4) (secondary use of identifiable private information). (Exemption ID: 1058; April 17, 2026).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors